Expert Ratings for Bio-Techne
Bio-Techne (NASDAQ:TECH) has observed the following analyst ratings within the last quarter: BullishSomewhat BullishIndifferentSomewhat BearishBearishTotal Ratings31200Last 30D100001M Ago000002M Ago21
UBS Initiates Coverage On Bio-Techne With Buy Rating, Announces Price Target of $80
UBS analyst Dan Leonard initiates coverage on Bio-Techne (NASDAQ:TECH) with a Buy rating and announces Price Target of $80.
Bio-Techne (NASDAQ:TECH) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe
BIO-TECHNE TO PRESENT AT THE 6TH ANNUAL EVERCORE ISI HEALTHCONx CONFERENCE
Bio-Techne Corporation (NASDAQ: TECH) today announced that Chuck Kummeth, President and Chief Executive Officer, and Kim Kelderman, Chief Operating...
Advancing With Stability: Bio-Techne Benefits Investors With Growing Earnings and Stable Payouts
By the close of today, November 24, 2023, Bio-Techne (NASDAQ:TECH) will issue a dividend payout of $0.08 per share, resulting in an annualized dividend yield of 0.56%. Only those investors who owned t
BIO-TECHNE TO PRESENT AT INVESTOR HEALTHCARE CONFERENCES
MINNEAPOLIS, Nov. 13, 2023 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: Stifel 2023 Healthcare ConferenceNovember
Positive Outlook for Bio-Techne Despite Challenges: An Analysis of Donnelly's Buy Rating Decision
A Look At The Intrinsic Value Of Bio-Techne Corporation (NASDAQ:TECH)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Bio-Techne fair value estimate is US$56.17 Bio-Techne's US$56.86 share price indicates it is trading at similar levels as its fair value esti
Bio-Techne (TECH) Receives a Buy From Stifel Nicolaus
Resilience and Growth Potential: Puneet Souda's Buy Rating and Long-term Confidence in Bio-Techne Despite Market Challenges
Bio-Techne To Go Ex-Dividend On November 9th, 2023 With 0.08 USD Dividend Per Share
November 2nd - $Bio-Techne(TECH.US)$ is trading ex-dividend on November 9th, 2023. Shareholders of record on November 10th, 2023 will receive 0.08 USD dividend per share on November 24th, 2023. Th
Stifel Maintains Buy on Bio-Techne, Lowers Price Target to $65
Stifel analyst Daniel Arias maintains Bio-Techne (NASDAQ:TECH) with a Buy and lowers the price target from $104 to $65.
Deutsche Bank Cuts Bio-Techne Price Target to $70 From $100, Maintains Buy Rating
Bio-Techne (TECH) has an average Buy rating and price target range of $65 to $99, according to analysts polled by Capital IQ. Price: 52.86, Change: -1.77, Percent Change: -3.24
Earnings Call: Bio-Techne Reports 2% Organic Growth Amid Biotech Funding Challenges
RBC Trims Price Target on Bio-Techne to $83 From $85, Keeps Sector Perform Rating
Bio-Techne (TECH) has an average investment rating of buy among analysts polled by Capital IQ, with price targets ranging from $65 to $99.
Analysts Offer Insights on Technology Companies: Match Group (MTCH), IPG Photonics (IPGP) and Bio-Techne (TECH)
Keybanc Maintains Overweight on Bio-Techne, Lowers Price Target to $80
Keybanc analyst Paul Knight maintains Bio-Techne (NASDAQ:TECH) with a Overweight and lowers the price target from $115 to $80.
Bio-Techne Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 11/01/2023 46.44% Keybanc $115 → $80 Maintains Overweight 09/12/2023 57.42% RBC Capital → $86 Reiterates S
Bio-Techne (TECH) Receives a Buy From Craig-Hallum
Bio-Techne Corp (TECH) Reports 2% Organic Revenue Growth in Q1 FY2024